CORRECTED: Novartis Knocks Colombia Over Leukemia Drug Price Control
Swiss pharmaceutical giant Novartis has threatened to file an investor-state claim against Colombia over the country's decision to require a price control on Novartis' leukemia drug Glivec, a spokesman for the...To view the full article, register now.
Already a subscriber? Click here to view full article